The Asia Pacific Minimal Residual Disease Testing Market should witness market growth of 15.3% CAGR during the forecast period (2022-2028).
Various institutions and organizations are researching the predictive significance of MRD tests in adult patients. Therefore, the outcomes of MRD investigations can be utilized to decide on the type and length of treatment, as well as to calculate the ideal window of time for hematopoietic stem cell transplantation (HSCT).
In addition, the discovery of new leukemia biomarkers and the application of increasingly accurate assays would make routine MRD monitoring even more manageable. This would further raise the significance of MRD tests and will contribute to a better understanding of the cellular and biological characteristics of leukemic cells that withstand chemotherapy in vivo.
The rising incidence of cancer worldwide and the higher acceptance of cancer therapies in developing nations are boosting the demand for MRD tests. The simultaneous shifts in healthcare from diagnosis of disease to early diagnosis or risk assessment and the expanding biomarkers' use in drug development are all contributing factors to the market's expansion.
Cancer is one of the leading causes of death in Asian nations. According to the National Cancer Center, three types of blood cancers, multiple lymphomas, malignant myelomas, and leukemia, also make up a portion of all cancers in Japan. The prevalence of cancer has sharply increased in recent years, and it is predicted that this trend will continue during the forecast period.
The China market dominated the Asia Pacific Minimal Residual Disease Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $211.1 million by 2028.The Japan market is experiencing a CAGR of 14.6% during (2022-2028). Additionally, The India market would display a CAGR of 16.1% during (2022-2028).
Based on Application, the market is segmented into Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors and Others. Based on End-user, the market is segmented into Hospitals & Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes and Others. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Flow Cytometry and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.
Various institutions and organizations are researching the predictive significance of MRD tests in adult patients. Therefore, the outcomes of MRD investigations can be utilized to decide on the type and length of treatment, as well as to calculate the ideal window of time for hematopoietic stem cell transplantation (HSCT).
In addition, the discovery of new leukemia biomarkers and the application of increasingly accurate assays would make routine MRD monitoring even more manageable. This would further raise the significance of MRD tests and will contribute to a better understanding of the cellular and biological characteristics of leukemic cells that withstand chemotherapy in vivo.
The rising incidence of cancer worldwide and the higher acceptance of cancer therapies in developing nations are boosting the demand for MRD tests. The simultaneous shifts in healthcare from diagnosis of disease to early diagnosis or risk assessment and the expanding biomarkers' use in drug development are all contributing factors to the market's expansion.
Cancer is one of the leading causes of death in Asian nations. According to the National Cancer Center, three types of blood cancers, multiple lymphomas, malignant myelomas, and leukemia, also make up a portion of all cancers in Japan. The prevalence of cancer has sharply increased in recent years, and it is predicted that this trend will continue during the forecast period.
The China market dominated the Asia Pacific Minimal Residual Disease Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $211.1 million by 2028.The Japan market is experiencing a CAGR of 14.6% during (2022-2028). Additionally, The India market would display a CAGR of 16.1% during (2022-2028).
Based on Application, the market is segmented into Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors and Others. Based on End-user, the market is segmented into Hospitals & Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes and Others. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Flow Cytometry and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.
Scope of the Study
By Application
- Hematological Malignancies
- Leukemia
- Lymphoma
- Solid Tumors
- Others
By End-user
- Hospitals & Specialty Clinics
- Diagnostic Laboratories
- Academic & Research Institutes
- Others
By Technology
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Flow Cytometry
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Bio-Rad Laboratories, Inc.
- Guardant Health, Inc.
- Invitae Corporation (ArcherDX, Inc.)
- Bio-Techne Corporation
- F.Hoffmann-La Roche Ltd.
- ICON plc (MolecularMD Corporation)
- Natera, Inc.
- Sysmex Corporation
- Laboratory Corporation of America Holdings
- Invivoscribe, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Minimal Residual Disease Testing Market, by Application
1.4.2 Asia Pacific Minimal Residual Disease Testing Market, by End User
1.4.3 Asia Pacific Minimal Residual Disease Testing Market, by Technology
1.4.4 Asia Pacific Minimal Residual Disease Testing Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Minimal Residual Disease Testing Market by Application
3.1 Asia Pacific Hematological Malignancies Market by Country
3.2 Asia Pacific Leukemia Market by Country
3.3 Asia Pacific Lymphoma Market by Country
3.4 Asia Pacific Solid Tumors Market by Country
3.5 Asia Pacific Others Market by Country
Chapter 4. Asia Pacific Minimal Residual Disease Testing Market by End User
4.1 Asia Pacific Hospitals & Specialty Clinics Market by Country
4.2 Asia Pacific Diagnostic Laboratories Market by Country
4.3 Asia Pacific Academic & Research Institutes Market by Country
4.4 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Minimal Residual Disease Testing Market by Technology
5.1 Asia Pacific Polymerase Chain Reaction (PCR) Market by Country
5.2 Asia Pacific Next-Generation Sequencing (NGS) Market by Country
5.3 Asia Pacific Flow Cytometry Market by Country
5.4 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Minimal Residual Disease Testing Market by Country
6.1 China Minimal Residual Disease Testing Market
6.1.1 China Minimal Residual Disease Testing Market by Application
6.1.2 China Minimal Residual Disease Testing Market by End User
6.1.3 China Minimal Residual Disease Testing Market by Technology
6.2 Japan Minimal Residual Disease Testing Market
6.2.1 Japan Minimal Residual Disease Testing Market by Application
6.2.2 Japan Minimal Residual Disease Testing Market by End User
6.2.3 Japan Minimal Residual Disease Testing Market by Technology
6.3 India Minimal Residual Disease Testing Market
6.3.1 India Minimal Residual Disease Testing Market by Application
6.3.2 India Minimal Residual Disease Testing Market by End User
6.3.3 India Minimal Residual Disease Testing Market by Technology
6.4 South Korea Minimal Residual Disease Testing Market
6.4.1 South Korea Minimal Residual Disease Testing Market by Application
6.4.2 South Korea Minimal Residual Disease Testing Market by End User
6.4.3 South Korea Minimal Residual Disease Testing Market by Technology
6.5 Singapore Minimal Residual Disease Testing Market
6.5.1 Singapore Minimal Residual Disease Testing Market by Application
6.5.2 Singapore Minimal Residual Disease Testing Market by End User
6.5.3 Singapore Minimal Residual Disease Testing Market by Technology
6.6 Malaysia Minimal Residual Disease Testing Market
6.6.1 Malaysia Minimal Residual Disease Testing Market by Application
6.6.2 Malaysia Minimal Residual Disease Testing Market by End User
6.6.3 Malaysia Minimal Residual Disease Testing Market by Technology
6.7 Rest of Asia Pacific Minimal Residual Disease Testing Market
6.7.1 Rest of Asia Pacific Minimal Residual Disease Testing Market by Application
6.7.2 Rest of Asia Pacific Minimal Residual Disease Testing Market by End User
6.7.3 Rest of Asia Pacific Minimal Residual Disease Testing Market by Technology
Chapter 7. Company Profiles
7.1 Bio-Rad Laboratories, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Guardant Health, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.3 Invitae Corporation (ArcherDX, Inc.)
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 Bio-Techne Corporation
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expenses
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Approvals & Trails:
7.6 ICON plc (MolecularMD Corporation)
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 Natera Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Sysmex Corporation
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.9 Laboratory Corporation of America Holdings
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental Analysis
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Product Launches and Product Expansions:
7.10. Invivoscribe, Inc.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Partnerships, Collaborations, and Agreements:
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Minimal Residual Disease Testing Market, by Application
1.4.2 Asia Pacific Minimal Residual Disease Testing Market, by End User
1.4.3 Asia Pacific Minimal Residual Disease Testing Market, by Technology
1.4.4 Asia Pacific Minimal Residual Disease Testing Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Minimal Residual Disease Testing Market by Application
3.1 Asia Pacific Hematological Malignancies Market by Country
3.2 Asia Pacific Leukemia Market by Country
3.3 Asia Pacific Lymphoma Market by Country
3.4 Asia Pacific Solid Tumors Market by Country
3.5 Asia Pacific Others Market by Country
Chapter 4. Asia Pacific Minimal Residual Disease Testing Market by End User
4.1 Asia Pacific Hospitals & Specialty Clinics Market by Country
4.2 Asia Pacific Diagnostic Laboratories Market by Country
4.3 Asia Pacific Academic & Research Institutes Market by Country
4.4 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Minimal Residual Disease Testing Market by Technology
5.1 Asia Pacific Polymerase Chain Reaction (PCR) Market by Country
5.2 Asia Pacific Next-Generation Sequencing (NGS) Market by Country
5.3 Asia Pacific Flow Cytometry Market by Country
5.4 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Minimal Residual Disease Testing Market by Country
6.1 China Minimal Residual Disease Testing Market
6.1.1 China Minimal Residual Disease Testing Market by Application
6.1.2 China Minimal Residual Disease Testing Market by End User
6.1.3 China Minimal Residual Disease Testing Market by Technology
6.2 Japan Minimal Residual Disease Testing Market
6.2.1 Japan Minimal Residual Disease Testing Market by Application
6.2.2 Japan Minimal Residual Disease Testing Market by End User
6.2.3 Japan Minimal Residual Disease Testing Market by Technology
6.3 India Minimal Residual Disease Testing Market
6.3.1 India Minimal Residual Disease Testing Market by Application
6.3.2 India Minimal Residual Disease Testing Market by End User
6.3.3 India Minimal Residual Disease Testing Market by Technology
6.4 South Korea Minimal Residual Disease Testing Market
6.4.1 South Korea Minimal Residual Disease Testing Market by Application
6.4.2 South Korea Minimal Residual Disease Testing Market by End User
6.4.3 South Korea Minimal Residual Disease Testing Market by Technology
6.5 Singapore Minimal Residual Disease Testing Market
6.5.1 Singapore Minimal Residual Disease Testing Market by Application
6.5.2 Singapore Minimal Residual Disease Testing Market by End User
6.5.3 Singapore Minimal Residual Disease Testing Market by Technology
6.6 Malaysia Minimal Residual Disease Testing Market
6.6.1 Malaysia Minimal Residual Disease Testing Market by Application
6.6.2 Malaysia Minimal Residual Disease Testing Market by End User
6.6.3 Malaysia Minimal Residual Disease Testing Market by Technology
6.7 Rest of Asia Pacific Minimal Residual Disease Testing Market
6.7.1 Rest of Asia Pacific Minimal Residual Disease Testing Market by Application
6.7.2 Rest of Asia Pacific Minimal Residual Disease Testing Market by End User
6.7.3 Rest of Asia Pacific Minimal Residual Disease Testing Market by Technology
Chapter 7. Company Profiles
7.1 Bio-Rad Laboratories, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Guardant Health, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.3 Invitae Corporation (ArcherDX, Inc.)
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 Bio-Techne Corporation
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expenses
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Approvals & Trails:
7.6 ICON plc (MolecularMD Corporation)
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 Natera Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Sysmex Corporation
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.9 Laboratory Corporation of America Holdings
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental Analysis
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Product Launches and Product Expansions:
7.10. Invivoscribe, Inc.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- Bio-Rad Laboratories, Inc.
- Guardant Health, Inc.
- Invitae Corporation (ArcherDX, Inc.)
- Bio-Techne Corporation
- F. Hoffmann-La Roche Ltd.
- ICON plc (MolecularMD Corporation)
- Natera, Inc.
- Sysmex Corporation
- Laboratory Corporation of America Holdings
- Invivoscribe, Inc.
Methodology
LOADING...
